Pozen Inc (POZN) 5.94 $POZN
Pernix Therapeutics Overcomes Challenge to Treximet(R) '183 Patent
GlobeNewswire - Mon May 09, 7:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced that on May 6, 2016, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied a petition for inter partes review (IPR) filed by Graybar Pharmaceuticals, LLC (now Gray Square Pharmaceuticals, LLC) against Pozen, Inc. This petition, which was filed on November 12, 2015, sought review of certain claims of U.S. Patent No. 7,332,183 ('183 patent), which expires 2026. The '183 patent is licensed by Pernix and is one of several FDA Orange Book listed patents covering Treximet(R), manufactured and sold by Pernix Therapeutics, (sumatriptan/naproxen sodium), a prescription medication for acute migraine attacks, with or without aura.
PTX: 0.59 (unch), POZN: 5.94 (-0.43)
Nuvo Pharmaceuticals™ Inc. announces appointment of Vice President, Business Development
PR Newswire - Mon Apr 04, 6:30AM CDT
Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced that Jesse Ledger has been appointed to the newly created position of Vice President, Business Development. Mr. Ledger will be responsible for all business development activities with an initial focus on maximizing the value of the Company's Pennsaid 2% franchise through global out-licensing.
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78), ARLZ: 5.00 (-0.02), POZN: 5.94 (-0.43)
Stroke - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/23dsxv/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Stroke Overview - Therapeutics Development - Pipeline Products for Stroke - Overview - Pipeline Products for Stroke - Comparative Analysis - Stroke - Therapeutics under Development by Companies - Stroke - Therapeutics under Investigation by Universities/Institutes - Stroke - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Stroke - Products under Development by Companies - Stroke - Products under Investigation by Universities/Institutes - Stroke - Companies Involved in Therapeutics Development Companies Mentioned Include: - AB Science SA - Acorda Therapeutics, Inc. - Acticor Biotech - Biogen, Inc. - BioTime, Inc. - Cardax Pharmaceuticals, Inc. - Cellular Biomedicine Group, Inc. - CHA Bio & Diostech Co., Ltd. - CoDa Therapeutics, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - NoNO, Inc. - Omeros Corporation - Panacea Pharmaceuticals, Inc. - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Phoenix Biotechnology, Inc. - Phylogica Limited - PhytoHealth Corporation - Pozen, Inc. - Primary Peptides, Inc. - (Others) For more information visit http://www.researchandmarkets.com/research/23...e_pipeline
ACOR: 24.27 (-0.07), POZN: 5.94 (-0.43), CBMG: 13.94 (-0.55), OMER: 11.10 (+0.34)
QLT Announces Closing of Acquisition of Shares of Aralez Pharmaceuticals Inc. and Special Distribution to Shareholders
GlobeNewswire - Fri Feb 05, 12:30PM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT"
today announces that it has acquired 7,200,000 common shares (the "Aralez Shares" of Aralez Pharmaceuticals Inc. ("Aralez" for a per share price of US$6.25 and an aggregate purchase price of US$45 million. Aralez is a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc. which completed today. Commencing on or about February 8, 2016, the common shares of Aralez will trade on NASDAQ under the ticker symbol "ARLZ", and on or about February 10, 2016, will trade on the Toronto Stock Exchange under the ticker symbol "ARZ". In connection with QLT's acquisition of the Aralez Shares, Jason Aryeh, the Chairman of QLT's board of directors, has been appointed to the board of directors of Aralez.
QLTI: 1.45 (-0.01), QLT.TO: 1.90 (unch), ARLZ: 5.00 (-0.02), POZN: 5.94 (-0.43)
POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.
PR Newswire - Fri Feb 05, 12:18PM CST
Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio-
TRX.VN: 1.250 (-0.070), ARZ.TO: 6.51 (unch), POZN: 5.94 (-0.43)
Global Pozen, Inc. Market Latest Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 6:56AM CST
'POZEN, INC. - Product Pipeline Review - 2015', provides an overview of the POZEN, INC.'s pharmaceutical research and development focus.
POZN: 5.94 (-0.43)
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
CNW Group - Thu Feb 04, 4:15PM CST
Tribute Pharmaceuticals Canada Inc. Removed from S&P/TSX Venture Indices
TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43), TRX: 0.92 (+0.13)
POZEN awarded stockholders' approval for Plan of Merger and Arrangement with Tribute Pharmaceuticals Canada
M2 - Wed Feb 03, 4:43AM CST
Specialist pharmaceutical company POZEN (NasdaqPOZN) said on Tuesday that its stockholders have approved the Agreement and Plan of Merger and Arrangement with Tribute Pharmaceuticals Canada.
ARLZ: 5.00 (-0.02), POZN: 5.94 (-0.43)
POZEN Inc. Announces Stockholder Approval of its Transaction with Tribute Pharmaceuticals Canada Inc.
CNW Group - Tue Feb 02, 8:00AM CST
-Transaction Expected to Close on or About February 5, 2016-
TRX.VN: 1.250 (-0.070), ARLZ: 5.00 (-0.02), POZN: 5.94 (-0.43)
Tribute Announces Results of Shareholder Vote
Marketwired - Mon Feb 01, 10:05AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it has received overwhelming shareholder approval of the previously announced plan of arrangement (the "Arrangement" with, among others, Aralez Pharmaceuticals Inc. ("Aralez" (see press release dated December 7, 2015), which forms part of the pending transaction with POZEN Inc. ("POZEN" (NASDAQ: POZN).
TRX.VN: 1.250 (-0.070), ARLZ: 5.00 (-0.02), POZN: 5.94 (-0.43)
Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.43 (-0.02), TRVN: 6.75 (-0.02), VRTX: 95.11 (+0.36), RDHL: 15.11 (+0.23), ZSAN: 0.81 (+0.04), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), ACOR: 24.27 (-0.07), NKTR: 18.45 (+0.34), AGN: 235.96 (-1.80), CORI: 5.75 (-0.05), ALDR: 31.52 (-1.02), CLCD: 10.66 (+0.41), MRK: 62.98 (+0.08), TEVA: 51.22 (+0.32), RVNC: 13.85 (-0.19), POZN: 5.94 (-0.43)
Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction
Marketwire Canada - Thu Jan 21, 6:30AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that Institutional Shareholder Services ("ISS" and Glass Lewis & Co. ("Glass Lewis" have both recommended that Tribute shareholders vote FOR the special resolution (the "Arrangement Resolution" to approve the previously announced transaction (the "Transaction" with Pozen Inc. ("Pozen" and combination under Aralez Pharmaceuticals Inc. ("Parent" , to be considered at the upcoming special meeting of Tribute shareholders to be held on February 1, 2016 at 10:00 a.m. (Toronto time) at the offices of Fogler, Rubinoff LLP, located at 77 King Street West, Suite 3000, Toronto, Ontario.
TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Tribute Mails Materials in Connection With Special Meeting of Shareholders to Approve Transaction With POZEN and Encourages Shareholders to Vote
Marketwired - Mon Jan 11, 8:43AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., announced that the Management Information Circular dated January 5, 2016 (the "Circular" and accompanying materials for Tribute's special meeting to be held on February 1, 2016 (the "Meeting" relating to the previously announced proposed transaction (the "Transaction" with POZEN Inc. ("POZEN" and combination under Aralez Pharmaceuticals Inc. ("Parent" , have been mailed to Tribute shareholders ("Tribute Shareholders" . These materials are available online at Tribute's website at www.tributepharma.com or on SEDAR at www.sedar.com and on the United States Securities and Exchange Commission (the "SEC" website at www.sec.gov.
TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Accretive Technologies Automates Financial Modeling with Novo34
PRWeb - Fri Jan 01, 7:06PM CST
Before making any important decisions, such as buying the stock of a company or deciding to invest in a business, investors build financial models that often take hours to put together. Advanced understanding of accounting and financial concepts, together with years of training are pre-requisites to developing effective financial modeling techniques.
POZN: 5.94 (-0.43)
RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016
Marketwired - Tue Dec 29, 7:01AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX) (OTCQX: TBUFF) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its special meeting of shareholders in connection with the pending transaction with POZEN Inc. ("POZEN" (NASDAQ: POZN) will be held on February 1, 2016 at 10:00 a.m. EST, at the offices of Fogler, Rubinoff LLP at Suite 3000, 77 King Street West, Toronto, Ontario. This meeting is being held to seek shareholder approval of the proposed transaction and related matters. Tribute is expected to mail the meeting materials in early January. Tribute's shareholders of record as of the close of business on December 31, 2015 are entitled to vote at the meeting.
TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Pernix Therapeutics Overcomes Challenge to Treximet(R) '183 Patent
GlobeNewswire - Mon May 09, 7:00AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced that on May 6, 2016, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) denied a petition for inter partes review (IPR) filed by Graybar Pharmaceuticals, LLC (now Gray Square Pharmaceuticals, LLC) against Pozen, Inc. This petition, which was filed on November 12, 2015, sought review of certain claims of U.S. Patent No. 7,332,183 ('183 patent), which expires 2026. The '183 patent is licensed by Pernix and is one of several FDA Orange Book listed patents covering Treximet(R), manufactured and sold by Pernix Therapeutics, (sumatriptan/naproxen sodium), a prescription medication for acute migraine attacks, with or without aura. PTX: 0.59 (unch), POZN: 5.94 (-0.43)
Nuvo Pharmaceuticals™ Inc. announces appointment of Vice President, Business Development
PR Newswire - Mon Apr 04, 6:30AM CDT
Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced that Jesse Ledger has been appointed to the newly created position of Vice President, Business Development. Mr. Ledger will be responsible for all business development activities with an initial focus on maximizing the value of the Company's Pennsaid 2% franchise through global out-licensing.
NRI.TO: 7.95 (-0.17), HZNP: 17.84 (-0.78), ARLZ: 5.00 (-0.02), POZN: 5.94 (-0.43)
Stroke - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/23dsxv/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Stroke Overview - Therapeutics Development - Pipeline Products for Stroke - Overview - Pipeline Products for Stroke - Comparative Analysis - Stroke - Therapeutics under Development by Companies - Stroke - Therapeutics under Investigation by Universities/Institutes - Stroke - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Stroke - Products under Development by Companies - Stroke - Products under Investigation by Universities/Institutes - Stroke - Companies Involved in Therapeutics Development Companies Mentioned Include: - AB Science SA - Acorda Therapeutics, Inc. - Acticor Biotech - Biogen, Inc. - BioTime, Inc. - Cardax Pharmaceuticals, Inc. - Cellular Biomedicine Group, Inc. - CHA Bio & Diostech Co., Ltd. - CoDa Therapeutics, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - NoNO, Inc. - Omeros Corporation - Panacea Pharmaceuticals, Inc. - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Phoenix Biotechnology, Inc. - Phylogica Limited - PhytoHealth Corporation - Pozen, Inc. - Primary Peptides, Inc. - (Others) For more information visit http://www.researchandmarkets.com/research/23...e_pipeline
ACOR: 24.27 (-0.07), POZN: 5.94 (-0.43), CBMG: 13.94 (-0.55), OMER: 11.10 (+0.34)
QLT Announces Closing of Acquisition of Shares of Aralez Pharmaceuticals Inc. and Special Distribution to Shareholders
GlobeNewswire - Fri Feb 05, 12:30PM CST
QLT Inc. (NASDAQ:QLTI) (TSX:QLT) ("QLT"
today announces that it has acquired 7,200,000 common shares (the "Aralez Shares" of Aralez Pharmaceuticals Inc. ("Aralez" for a per share price of US$6.25 and an aggregate purchase price of US$45 million. Aralez is a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc. which completed today. Commencing on or about February 8, 2016, the common shares of Aralez will trade on NASDAQ under the ticker symbol "ARLZ", and on or about February 10, 2016, will trade on the Toronto Stock Exchange under the ticker symbol "ARZ". In connection with QLT's acquisition of the Aralez Shares, Jason Aryeh, the Chairman of QLT's board of directors, has been appointed to the board of directors of Aralez. QLTI: 1.45 (-0.01), QLT.TO: 1.90 (unch), ARLZ: 5.00 (-0.02), POZN: 5.94 (-0.43)
POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.
PR Newswire - Fri Feb 05, 12:18PM CST
Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio-
TRX.VN: 1.250 (-0.070), ARZ.TO: 6.51 (unch), POZN: 5.94 (-0.43)
Global Pozen, Inc. Market Latest Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 6:56AM CST
'POZEN, INC. - Product Pipeline Review - 2015', provides an overview of the POZEN, INC.'s pharmaceutical research and development focus.
POZN: 5.94 (-0.43)
S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian Indices
CNW Group - Thu Feb 04, 4:15PM CST
Tribute Pharmaceuticals Canada Inc. Removed from S&P/TSX Venture Indices
TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43), TRX: 0.92 (+0.13)
POZEN awarded stockholders' approval for Plan of Merger and Arrangement with Tribute Pharmaceuticals Canada
M2 - Wed Feb 03, 4:43AM CST
Specialist pharmaceutical company POZEN (NasdaqPOZN) said on Tuesday that its stockholders have approved the Agreement and Plan of Merger and Arrangement with Tribute Pharmaceuticals Canada.
ARLZ: 5.00 (-0.02), POZN: 5.94 (-0.43)
POZEN Inc. Announces Stockholder Approval of its Transaction with Tribute Pharmaceuticals Canada Inc.
CNW Group - Tue Feb 02, 8:00AM CST
-Transaction Expected to Close on or About February 5, 2016-
TRX.VN: 1.250 (-0.070), ARLZ: 5.00 (-0.02), POZN: 5.94 (-0.43)
Tribute Announces Results of Shareholder Vote
Marketwired - Mon Feb 01, 10:05AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it has received overwhelming shareholder approval of the previously announced plan of arrangement (the "Arrangement" with, among others, Aralez Pharmaceuticals Inc. ("Aralez" (see press release dated December 7, 2015), which forms part of the pending transaction with POZEN Inc. ("POZEN" (NASDAQ: POZN). TRX.VN: 1.250 (-0.070), ARLZ: 5.00 (-0.02), POZN: 5.94 (-0.43)
Migraine Therapeutic Development Pipeline Review, H2 2015
M2 - Thu Jan 28, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/tw7v3m/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Migraine Overview - Therapeutics Development - Pipeline Products for Migraine - Overview - Pipeline Products for Migraine - Comparative Analysis - Migraine - Therapeutics under Development by Companies - Migraine - Therapeutics under Investigation by Universities/Institutes - Migraine - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Migraine - Products under Development by Companies - Migraine - Products under Investigation by Universities/Institutes - Migraine - Companies Involved in Therapeutics Development - Ache Laboratorios Farmaceuticos S/A - Acorda Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - Alder Biopharmaceuticals Inc. - Allergan Plc - Amgen Inc. - Astellas Pharma Inc. - BioDelivery Sciences International, Inc. - Biofrontera AG - Charleston Laboratories, Inc. - CoLucid Pharmaceuticals, Inc. - Corium International, Inc. - D-Pharm Ltd. - Eli Lilly and Company - iCeutica, Inc. - Impel NeuroPharma, Inc. - Mallinckrodt Plc - Medestea Research & Production S.p.A. - Merck & Co., Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Nektar Therapeutics - Noxxon Pharma AG - Otsuka Holdings Co., Ltd. - Pantarhei Bioscience BV - Pivot Pharmaceuticals Inc - Pozen, Inc. - Promius Pharma, LLC - RedHill Biopharma Ltd. - Revance Therapeutics, Inc. - Shin Nippon Biomedical Laboratories, Ltd. - Suda Ltd - Teva Pharmaceutical Industries Limited - TheraJect, Inc. - Trevena, Inc. - Trigemina, Inc. - Vertex Pharmaceuticals Incorporated - Zosano Pharma Corporation For more information visit http://www.researchandmarkets.com/research/tw7v3m/migraine
BDSI: 2.43 (-0.02), TRVN: 6.75 (-0.02), VRTX: 95.11 (+0.36), RDHL: 15.11 (+0.23), ZSAN: 0.81 (+0.04), AMGN: 169.77 (-0.36), LLY: 76.85 (-0.38), ACOR: 24.27 (-0.07), NKTR: 18.45 (+0.34), AGN: 235.96 (-1.80), CORI: 5.75 (-0.05), ALDR: 31.52 (-1.02), CLCD: 10.66 (+0.41), MRK: 62.98 (+0.08), TEVA: 51.22 (+0.32), RVNC: 13.85 (-0.19), POZN: 5.94 (-0.43)
Leading Independent Advisors Recommend That Tribute Shareholders Vote FOR the Transaction
Marketwire Canada - Thu Jan 21, 6:30AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., is pleased to announce that Institutional Shareholder Services ("ISS" and Glass Lewis & Co. ("Glass Lewis" have both recommended that Tribute shareholders vote FOR the special resolution (the "Arrangement Resolution" to approve the previously announced transaction (the "Transaction" with Pozen Inc. ("Pozen" and combination under Aralez Pharmaceuticals Inc. ("Parent" , to be considered at the upcoming special meeting of Tribute shareholders to be held on February 1, 2016 at 10:00 a.m. (Toronto time) at the offices of Fogler, Rubinoff LLP, located at 77 King Street West, Suite 3000, Toronto, Ontario. TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Tribute Mails Materials in Connection With Special Meeting of Shareholders to Approve Transaction With POZEN and Encourages Shareholders to Vote
Marketwired - Mon Jan 11, 8:43AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., announced that the Management Information Circular dated January 5, 2016 (the "Circular" and accompanying materials for Tribute's special meeting to be held on February 1, 2016 (the "Meeting" relating to the previously announced proposed transaction (the "Transaction" with POZEN Inc. ("POZEN" and combination under Aralez Pharmaceuticals Inc. ("Parent" , have been mailed to Tribute shareholders ("Tribute Shareholders" . These materials are available online at Tribute's website at www.tributepharma.com or on SEDAR at www.sedar.com and on the United States Securities and Exchange Commission (the "SEC" website at www.sec.gov. TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
Accretive Technologies Automates Financial Modeling with Novo34
PRWeb - Fri Jan 01, 7:06PM CST
Before making any important decisions, such as buying the stock of a company or deciding to invest in a business, investors build financial models that often take hours to put together. Advanced understanding of accounting and financial concepts, together with years of training are pre-requisites to developing effective financial modeling techniques.
POZN: 5.94 (-0.43)
RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016
Marketwired - Tue Dec 29, 7:01AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX) (OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its special meeting of shareholders in connection with the pending transaction with POZEN Inc. ("POZEN" (NASDAQ: POZN) will be held on February 1, 2016 at 10:00 a.m. EST, at the offices of Fogler, Rubinoff LLP at Suite 3000, 77 King Street West, Toronto, Ontario. This meeting is being held to seek shareholder approval of the proposed transaction and related matters. Tribute is expected to mail the meeting materials in early January. Tribute's shareholders of record as of the close of business on December 31, 2015 are entitled to vote at the meeting. TRX.VN: 1.250 (-0.070), POZN: 5.94 (-0.43)
